## VEGFR3, Fc Fusion, Avi-Tag, Recombinant

Catalog: 102101 Lot: 240124-1

Product Information	
Description:	Recombinant human VEGFR3 (vascular endothelial growth factor receptor 3), encompassing amino acids 25-776. This construct contains a C-terminal Factor Xa sequence and a human Fc domain of IgG1 followed by an Avi-Tag <sup>™</sup> . This protein was affinity purified.
Background:	VEGFR3 (vascular endothelial growth factor receptor 3) is one of three VEGFRs and has VEFGC and VEGFD as ligands. Its main roles are in angiogenesis, lymphangiogenesis, and vasculogenesis. VEGFR3 is cleaved within its immunoglobulin-like domain, resulting in two peptides that bind together via a disulphide bond and get integrated into the cell membrane. This protein can exist as three isoforms: full length, an isoform missing 65 amino acids on the C-terminus and a third isoform missing a larger fraction of the C- terminus. This third is soluble and seems to function in sequestering VEGFC in the retina. VEGFR3 can form heterodimers with VEFGR2 and bind VEGFC, functioning in angiogenesis and hematopoiesis. Dysfunction of this protein can result in Milroy disease, congenital heart disease and cancer. The use of inhibitors targeting VEGFR3 can reduce angiogenesis and be beneficial in cancer therapy.
Species:	Human
Construct:	VEGFR3 (25-776-Fc(lgG1)-Avi)
Concentration:	1.24 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	114 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank Accession:	NM_182925
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Applications:	Useful for SDS-PAGE.

**Quality Control Data** 

## 4-20% SDS-PAGE Coomassie Staining

